Friends Of Cancer Research, ACS CAN Urge Congress To Pass VALID

By Lia DeGroot / November 30, 2022 at 3:59 PM
Two leading cancer research advocacy groups are calling on Congress to pass a key diagnostics reform bill, arguing that laboratory-developed tests (LDTs) used to determine treatment for cancer patients are not regulated closely enough and lead to unreliable test results that can impede access to safe and effective treatment. Lisa Lacasse, president of the American Cancer Society Cancer Action Network and Jeff Allen, president and CEO of Friends of Cancer Research, wrote in an op-ed published in STAT Wednesday...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.